0%
Loading ...

If a change in the ovary is detected during a gynecological examination or ultrasound, your doctor may recommend additional tests to further evaluate the finding. One of the tools that can help assess the risk is the ROMA Index.

ROMA stands for Risk of Ovarian Malignancy Algorithm.

What exactly is the ROMA Index?

The ROMA Index is a laboratory algorithm that combines the results of two tumor markers: CA-125 and HE4 (Human Epididymis Protein 4), together with information on whether a woman is premenopausal or postmenopausal.

By combining these results and menopausal status, the algorithm provides a value that can help the doctor assess the risk of a malignant ovarian condition in women who have an ovarian or adnexal mass.

Why are CA-125 and HE4 combined?

CA-125 is a marker that can be elevated in certain ovarian conditions, but also in some benign conditions. HE4 is another biomarker used in the assessment of epithelial ovarian cancer. When these two results are considered together with menopausal status, the ROMA algorithm can provide additional information for risk assessment.

Who may be recommended to have it?

The ROMA Index is not a test that every woman should routinely have.

It is intended to assist in the assessment of women who have been found to have an adnexal or ovarian mass, together with the clinical examination and imaging findings. The result may help the doctor decide whether further evaluation or referral to a gynecologic oncologist is needed.

It is important to know:

A high ROMA result does not mean that a woman has ovarian cancer.

Likewise, a low result should not be interpreted on its own. ROMA is an additional tool and should be interpreted together with the gynecological examination, medical history, and ultrasound or other imaging results.

Why is menopausal status important?

The ROMA algorithm takes into account the differences between premenopausal and postmenopausal women. Therefore, menopausal status is an important part of interpreting the result and should not be overlooked.

ROMA is not a substitute for a gynecological examination

Although it is a laboratory parameter, the ROMA Index should not be considered a standalone test that can establish a diagnosis.

It is part of a broader clinical assessment, particularly when an ovarian or adnexal mass has already been identified. The doctor considers all available information before deciding on further monitoring or diagnostic evaluation.

Remember:

ROMA Index does not tell you “whether you have cancer.”

It provides additional information for risk assessment in a specific group of patients and should always be interpreted in the appropriate clinical context.

When laboratory results, gynecological examination and diagnostic imaging are considered together, the doctor can gain a more complete picture of the patient’s condition.